Company Profile
Kazia Therapeutics Limited Stock Price, News & Analysis
- Ticker:
- KZIA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
12.33 USD (+2.75%)
Close
Last updated: August 6, 2026
135M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KZIA closed up 2.75% at $12.33. No new same-company headline was identified in the current news window.
Company overview
Business overview
Kazia Therapeutics is an oncology biotechnology company focused on targeted cancer therapies, including programs aimed at difficult solid tumors and brain tumors. Its story is built around trying to create meaningful value from a specialized oncology pipeline.
Geographic Base and Sector Classification
Kazia is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, translational confidence, and the ability to fund a narrow cancer pipeline. Investors usually watch proof-of-concept work and strategic changes.
Position Within the Biotechnology Landscape
Kazia occupies a specialized oncology niche within biotech. It is highly catalyst-sensitive because the company is still proving whether the platform can matter clinically.
Future catalysts
Kazia’s catalysts are paxalisib and the oncology / brain-cancer program, where the next update can materially change the market’s view. The stock remains very much a data story.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kazia Therapeutics Limited (KZIA)?
Kazia Therapeutics Limited (KZIA) most recently closed at 12.33 USD, a +2.75% move versus the previous session.
What is the market cap of Kazia Therapeutics Limited (KZIA)?
Kazia Therapeutics Limited currently has a market capitalization of 135M USD on BioPharmSignal.
What does Kazia Therapeutics Limited do?
Kazia Therapeutics is an oncology biotechnology company focused on targeted cancer therapies, including programs aimed at difficult solid tumors and brain tumors. Its story is built around trying to create meaningful value from a specialized oncology pipeline.
On which exchange is KZIA stock listed?
Kazia Therapeutics Limited (KZIA) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is Kazia?
Kazia’s catalysts are paxalisib and the oncology / brain-cancer program, where the next update can materially change the market’s view.
Which conditions is Kazia Therapeutics Limited targeting with Kazia?
Kazia Therapeutics Limited is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Kazia Therapeutics Limited describe recent progress with Kazia?
Kazia’s catalysts are paxalisib and the oncology / brain-cancer program, where the next update can materially change the market’s view.
What is Therapeutics?
Kazia Therapeutics is an oncology biotechnology company focused on targeted cancer therapies, including programs aimed at difficult solid tumors and brain tumors.